Central stimulation of renin secretion through serotonergic, noncardiovascular mechanisms. 1994

P A Rittenhouse, and E A Bakkum, and A D Levy, and Q Li, and J M Yracheta, and K Kunimoto, and L D van de Kar
Department of Pharmacology, Stritch School of Medicine, Loyola University Chicago, Maywood, Ill 60153.

The aims of the study were to determine; (1) whether activation of serotonin (5-HT) receptors in the brain increases renin secretion, and (2) whether the hypertensive effects of a 5-HT agonist and 5-HT releaser obscure their ability to stimulate renin release. Various drugs that increase serotonergic neuro-transmission can activate the secretion of renin from the kidneys. Many of these drugs can also elevate blood pressure. Changes in blood pressure can alter renin secretion by activating renal baroreceptor mechanisms, so that a decrease in perfusion pressure will increase renin secretion and vice versa. To address the first objective, the 5-HT agonist RU 24969 (0, 10, 100 and 200 micrograms/kg) and the 5-HT releaser p-chloroamphetamine (0, 50, 500 and 1,000 micrograms/kg) were injected intracerebroventricularly (ICV) at doses lower than those that are peripherally effective. ICV injection of RU 24969 dose-dependently increased plasma levels of renin. ICV injection of the 5-HT2A/5-HT2C antagonist LY53857 (50 micrograms/kg) inhibited the renin response to peripherally injected RU 24969 (0, 1, 5 and 10 mg/kg i.p.), suggesting that 5-HT2A/5-HT2C receptors in the brain mediate the effect of peripherally injected RU 24969 on renin secretion. In contrast, ICV injection of p-chloroamphetamine decreased renin secretion. To determine whether hypertensive actions could account for the differences between RU 24969 and p-chloroamphetamine, we measured the effects of both p-chloroamphetamine and RU 24969 on blood pressure and heart rate. ICV injection of p-chloroamphetamine (1,000 micrograms/kg) produced a large rise of 44 mm Hg at 2 min and 25 mm Hg at 5 min after injection, while ICV injection of RU 24969 (200 micrograms/kg) caused a slower and smaller blood pressure elevation of 18 mm Hg at 5 min after injection. To determine whether the hypertensive effects of both RU 24969 and p-chloroamphetamine could mask their effects on renin secretion, rats were pretreated with the alpha 1 antagonist prazosin. Administration of prazosin (1 mg/kg s.c.), which prevents the hypertensive effects of p-chloroamphetamine, exposed a stimulatory effect of ICV-injected p-chloroamphetamine (500 micrograms/kg) on renin secretion and potentiated the effect of RU 24969 (5 mg/kg i.p.) on renin release. In conclusion, these data suggest that both RU 24969 and p-chloroamphetamine increase renin secretion through central 5-HT receptors, and that these effects are partially obscured by their hypertensive actions.

UI MeSH Term Description Entries
D007211 Indoles Benzopyrroles with the nitrogen at the number one carbon adjacent to the benzyl portion, in contrast to ISOINDOLES which have the nitrogen away from the six-membered ring.
D007276 Injections, Intraventricular Injections into the cerebral ventricles. Intraventricular Injections,Injection, Intraventricular,Intraventricular Injection
D008297 Male Males
D010133 p-Chloroamphetamine Chlorinated analog of AMPHETAMINE. Potent neurotoxin that causes release and eventually depletion of serotonin in the CNS. It is used as a research tool. p-Chloramphetamine,para-Chloroamphetamine,LY-121860,Ly-123362,Parachloroamphetamine,LY 121860,LY121860,Ly 123362,Ly123362,p Chloramphetamine,p Chloroamphetamine,para Chloroamphetamine
D011224 Prazosin A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION. Furazosin,Minipress,Pratsiol,Prazosin HCL,Prazosin Hydrochloride,HCL, Prazosin,Hydrochloride, Prazosin
D012083 Renin A highly specific (Leu-Leu) endopeptidase that generates ANGIOTENSIN I from its precursor ANGIOTENSINOGEN, leading to a cascade of reactions which elevate BLOOD PRESSURE and increase sodium retention by the kidney in the RENIN-ANGIOTENSIN SYSTEM. The enzyme was formerly listed as EC 3.4.99.19. Angiotensin-Forming Enzyme,Angiotensinogenase,Big Renin,Cryorenin,Inactive Renin,Pre-Prorenin,Preprorenin,Prorenin,Angiotensin Forming Enzyme,Pre Prorenin,Renin, Big,Renin, Inactive
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D002320 Cardiovascular Physiological Phenomena Processes and properties of the CARDIOVASCULAR SYSTEM as a whole or of any of its parts. Cardiovascular Physiologic Processes,Cardiovascular Physiological Processes,Cardiovascular Physiology,Cardiovascular Physiological Concepts,Cardiovascular Physiological Phenomenon,Cardiovascular Physiological Process,Physiology, Cardiovascular,Cardiovascular Physiological Concept,Cardiovascular Physiological Phenomenas,Concept, Cardiovascular Physiological,Concepts, Cardiovascular Physiological,Phenomena, Cardiovascular Physiological,Phenomenon, Cardiovascular Physiological,Physiologic Processes, Cardiovascular,Physiological Concept, Cardiovascular,Physiological Concepts, Cardiovascular,Physiological Phenomena, Cardiovascular,Physiological Phenomenon, Cardiovascular,Physiological Process, Cardiovascular,Physiological Processes, Cardiovascular,Process, Cardiovascular Physiological,Processes, Cardiovascular Physiologic,Processes, Cardiovascular Physiological
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug

Related Publications

P A Rittenhouse, and E A Bakkum, and A D Levy, and Q Li, and J M Yracheta, and K Kunimoto, and L D van de Kar
January 1980, Neuroendocrinology,
P A Rittenhouse, and E A Bakkum, and A D Levy, and Q Li, and J M Yracheta, and K Kunimoto, and L D van de Kar
October 1985, The Journal of clinical investigation,
P A Rittenhouse, and E A Bakkum, and A D Levy, and Q Li, and J M Yracheta, and K Kunimoto, and L D van de Kar
July 1992, Pharmacology, biochemistry, and behavior,
P A Rittenhouse, and E A Bakkum, and A D Levy, and Q Li, and J M Yracheta, and K Kunimoto, and L D van de Kar
January 1982, Neuroendocrinology,
P A Rittenhouse, and E A Bakkum, and A D Levy, and Q Li, and J M Yracheta, and K Kunimoto, and L D van de Kar
October 1992, Brain research,
P A Rittenhouse, and E A Bakkum, and A D Levy, and Q Li, and J M Yracheta, and K Kunimoto, and L D van de Kar
January 1996, Behavioural brain research,
P A Rittenhouse, and E A Bakkum, and A D Levy, and Q Li, and J M Yracheta, and K Kunimoto, and L D van de Kar
September 1979, Life sciences,
P A Rittenhouse, and E A Bakkum, and A D Levy, and Q Li, and J M Yracheta, and K Kunimoto, and L D van de Kar
January 1988, American journal of hypertension,
P A Rittenhouse, and E A Bakkum, and A D Levy, and Q Li, and J M Yracheta, and K Kunimoto, and L D van de Kar
December 1983, Federation proceedings,
P A Rittenhouse, and E A Bakkum, and A D Levy, and Q Li, and J M Yracheta, and K Kunimoto, and L D van de Kar
March 2013, Veterinary research communications,
Copied contents to your clipboard!